Drug recall · February 26, 2020
Glycopyrrolate Injection recall
Why: Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.
- Lots / codes
Lot #CGP190001-A, Exp. 07/31/2020
- Quantity
- 4600 Vials
- Company
- AuroMedics Pharma LLC, East Windsor, NJ
- Distribution
- Ohio, Louisiana, Mississippi
- Initiated
- February 7, 2020 · Voluntary: Firm initiated
- Classified
- February 20, 2020
- Reported
- February 26, 2020
- Ended
- March 8, 2023
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.